Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 16/20 | 0.72 |
| ▸ | CCNT1 | O60563 | 15/20 | 0.72 |
| ▸ | CDK2 | P24941 | 4/20 | 0.72 |
| ▸ | GSK3A | P49840 | 4/20 | 0.72 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.72 |
| ▸ | CDK1 | P06493 | 3/20 | 0.72 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.72 |
| ▸ | ABL2 | P42684 | 3/20 | 0.72 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.72 |
| ▸ | CDK4 | P11802 | 2/20 | 0.72 |
| ▸ | CCND1 | P24385 | 2/20 | 0.72 |
| ▸ | CDK7 | P50613 | 2/20 | 0.72 |
| ▸ | CCNH | P51946 | 2/20 | 0.72 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.72 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.72 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.72 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.72 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.53 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060209 | 1.00 | CDK9 (0.72) | CDK9CCNT1CDK2GSK3AMAP4K4 | |
| SCHEMBL12487288 | 0.90 | CDK9 (0.67) | CDK9CCNT1CDK2GSK3AMAP4K4 | |
| SCHEMBL12485959 | 0.90 | CDK9 (0.59) | CDK9CCNT1CDK2GSK3AMAP4K4 | |
| SCHEMBL12487274 | 0.84 | CDK9 (0.70) | CDK9CCNT1CDK2GSK3AMAP4K4 | |
| SCHEMBL4430368 | 0.84 | CDK9 (1.00) | CDK9CCNT1CDK2GSK3AMAP4K4 | |
| SCHEMBL29486339 | 0.84 | CDK9 (1.00) | CDK9CCNT1CDK2GSK3AMAP4K4 | |
| SCHEMBL3005997 | 0.82 | CDK9 (0.70) | CDK9CCNT1CDK2GSK3AMAP4K4 | |
| SCHEMBL17257720 | 0.81 | CDK9 (0.70) | CDK9CCNT1CDK2GSK3AMAP4K4 | |
| SCHEMBL12486011 | 0.81 | CDK9 (0.66) | CDK9CCNT1CDK2GSK3AMAP4K4 | |
| SCHEMBL16108038 | 0.81 | CDK9 (0.52) | CDK9CCNT1CDK2GSK3AMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2748331-B1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2016-03-02 | — | — | EP | claimed |
| US-9242937-B2 | Pharmaceutically active disubstituted pyridine derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-26 | — | — | US | claimed |
| EP-2681193-B1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED PYRIDINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2016-01-06 | — | — | EP | claimed |
| US-20150329537-A2 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | LEADDISCOVERY CENTER GMBH (DE) | 2015-11-19 | — | — | US | claimed |
| US-20140303167-A1 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | LEAD DISCOVERY CENTER GMBH (DE) | 2014-10-09 | — | — | US | claimed |
| US-20140296304-A1 | Pharmaceutically Active Disubstituted Pyridine Derivatives | LEAD DISCOVERY CENTER GMBH (DE) | 2014-10-02 | — | — | US | claimed |
| US-20140287454-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-09-25 | — | — | US | claimed |
| EP-2748331-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | Lead Discovery Center GmbH (DE) | 2014-07-02 | — | — | EP | claimed |
| EP-2681193-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED PYRIDINE DERIVATIVES | Lead Discovery Center GmbH (DE) | 2014-01-08 | — | — | EP | claimed |
| WO-2013026890-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2013-02-28 | — | — | WO | claimed |
| EP-2562265-A1 | Susceptibility to selective CDK9 inhibitors | Lead Discovery Center GmbH (DE) | 2013-02-27 | — | — | EP | claimed |
| WO-2012117059-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED PYRIDINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2012-09-07 | — | — | WO | claimed |
| EP-2748331-B1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2016-03-02 | — | — | EP | disclosed |
| US-9242937-B2 | Pharmaceutically active disubstituted pyridine derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| US-9242937-B2 | Pharmaceutically active disubstituted pyridine derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| US-9242937-B2 | Pharmaceutically active disubstituted pyridine derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| US-20140287454-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-09-25 | — | — | US | disclosed |
| US-20140287454-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-09-25 | — | — | US | disclosed |
| EP-2561867-A1 | CDK9 inhibitors in the treatment of midline carcinoma | Lead Discovery Center GmbH (DE) | 2013-02-27 | — | — | EP | disclosed |
| EP-2562265-A1 | Susceptibility to selective CDK9 inhibitors | Lead Discovery Center GmbH (DE) | 2013-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296304-A1 | Pharmaceutically Active Disubstituted Pyridine Derivatives | PINK1, PDPK1, LCK | CDK9 324/4885CCNT1 3091/4885CDK2 542/4885 |
| US-20150329537-A2 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | CDK9, CDK19, CDKN1A | CDK9 1/4885CCNT1 41/4885CDK2 27/4885 |
| US-20140303167-A1 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | CDK9, CDK19, CDKN1A | CDK9 1/4885CCNT1 41/4885CDK2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.